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Matthias Nahrendorf, MD, PHD, Filip K. Swirski, PHDM yocardial infarction (MI) remains one ofthe most common health emergencies,and a sizable fraction of acute MI patients
develop subsequent complications (1). Despite
guideline-adherent therapy, post-MI heart failure
occurs, motivating efforts to identify patients at risk
and to develop novel therapeutic strategies. Increas-
ingly, cardiologists are looking at the immune
system’s role in the repair of the ischemic heart, and
systemic inﬂammatory networks that could be
targeted to oppose progression of ischemic heart
disease. Two hurdles block our path to new therapeu-
tics: the heterogeneity of the immune response in
individual patients, and the detrimental as well asSEE PAGES 1417 AND 1466protective consequences of immune system activa-
tion on the organism. These hurdles may be over-
come with improved surveillance of immune cell
activity in cardiovascular organs, as this would
enable patient selection and therapeutic monitoring.
Similar strategies are being pursued in oncology
where speciﬁc types of cancer are treated with
personalized therapeutics, and increasingly, drug
development is guided by tailored companion-
imaging approaches. In this issue of iJACC, 2 articles
introduce a promising positron-emission tomography
(PET) imaging approach to monitor the presence of
immune cells in the acute infarct of patients with
ischemic heart disease (2,3).
Both studies investigate an imaging agent that
binds to the chemokine receptor CXCR4. The small
molecule PET tracer 68Ga-pentixafor has advanced*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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applications (4), where the imaging agent may report
on therapeutics that interfere with CXCR4 signaling
(5). CXCR4 and its ligand SDF-1 are widely ex-
pressed in the steady-state. Among other functions,
the chemokine/chemokine receptor pair regulates the
activity and migration of hematopoietic stem cells and
leukocytes, including neutrophils and monocytes.
The latter innate immune cells promote ischemic
heart disease and are central regulators of infarct
healing and regeneration (1). After MI, inﬂammatory
neutrophils and monocytes are released from the
bone marrow and spleen, where they are produced
from hematopoietic stem and progenitor cells
(Figure 1). Interestingly, post-MI proliferation and
migration of hematopoietic progenitor cells is regu-
lated by CXCR4 (6). Once recruited to the infarct,
phagocytic immune cells remove dead stromal cells.
After 3 to 4 days, inﬂammation begins to resolve,
while neutrophil numbers decline and macrophages
assume less inﬂammatory functions. This transition
from inﬂammation to resolution supports repair;
however, if it is delayed, for instance, due to over-
supply of inﬂammatory immune cells, post-MI
remodeling and heart failure are more likely to occur
(7). These aspects have been studied in detail on the
tissue level in rodents, but blood monocyte levels
likewise correlate with outcome in human patients
with acute MI (1). To date, it has been difﬁcult to im-
age infarct inﬂammation in the human heart. One
exception is 18F-FDG, which enriches in acute infarcts
(8) but suffers from speciﬁcity limitations as this
tracer may be taken up by cardiomyocytes. Infarct-
induced bone marrow proliferation may be assessed
by PET imaging after injection the thymidine analog
18F-FLT (9), but this agent is not cell-speciﬁc either.
Thus, speciﬁc imaging agents, which only bind to
certain leukocytes and not to stromal cells, are
needed.
In a comprehensive study in mice and humans,
Thackeray et al. (3) describe that 68Ga-pentixafor
FIGURE 1 Cell Flux and the Imaging Target CXCR4 After
Acute Myocardial Infarction
After myocardial infarction, increased hematopoiesis in
spleen and bone marrow supplies innate immune cells
(neutrophils, monocytes) to the infarct. These cells, and their
progenitors in hematopoietic tissues, express CXCR4, a
chemokine receptor that serves as an imaging target in
the discussed manuscripts.
Nahrendorf and Swirski J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 1 2 , 2 0 1 5
Editorial Comment D E C E M B E R 2 0 1 5 : 1 4 2 7 – 9
1428enriches in acute infarcts. PET signal was higher at
earlier times after coronary ligation; was blocked
with a CXCR4 inhibitor; and attenuated by applica-
tion of an angiotensin-converting enzyme (ACE)
inhibitor, standard post-MI treatment that was
previously shown to attenuate the splenic supply of
immune cells to the acute infarct (8). The in-
vestigators also report 68Ga-pentixafor PET imaging
in 12 patients. The PET signal varied and not all
infarcted segments were positive. 68Ga-pentixafor
enrichment was low in normal myocardium and
highest early after MI and in myocardial segments
that were severely damaged (indicated by lowest
perfusion on single-photon emission computed
tomography, highest scores for delayed Gd enhance-
ment and edema on cardiac magnetic resonance).
Tracer uptake in hematopoietic organs was detected,
especially in the spleen, and correlated to imaging
signal observed in the heart.
The paper by Lapa et al. (2) parallels these
ﬁndings in patients 5 to 10 days after acute MI.
68Ga-pentixafor PET signal in the infarct, which was
identiﬁed by delayed Gd enhancement magneticresonance imaging, was observed in 3 of 7 investi-
gated patients. Taken together, both studies indicate
speciﬁc uptake in some infarcted segments, no up-
take in other infarcted segments, and agree that the
remote, noninfarcted myocardium shows low PET
signal.
How cell-speciﬁc is 68Ga-pentixafor? The data from
blocking experiments (3) suggest speciﬁcity for
CXCR4, which is quite widely expressed by different
leukocytes. These include tissue resident macro-
phages, circulating neutrophils and monocytes, lym-
phocytes, and hematopoietic progenitors (10). Some
reports (11,12) describe expression of CXCR4 by car-
diomyocytes and cardiac ﬁbroblasts. The healthy, but
particularly the ischemic myocardium, contains a
robust number of leukocytes (7). The typical
methods to isolate cardiomyocytes and cardiac ﬁ-
broblasts do not involve antigen-speciﬁc cell sort-
ing. The resulting stromal cell population is thus
likely contaminated with inﬁltrating leukocytes
and/or tissue resident macrophages, which express
high levels of CXCR4. Close examination of immu-
noreactive histology (13) suggests that the receptor
is, at least in some cases, expressed by non-
cardiomyocytes. Thus, evidence for the expression
of the chemokine receptor by cardiomyocytes is less
compelling. In addition, Thackeray et al. (3) used
permanent LAD occlusion in mice. Four days after
MI, ischemia has killed most myocytes in the infarct
zone, where the agent uptake was high. The current
studies do not deﬁnitely answer which cells are
targeted by 68Ga-pentixafor, although the associa-
tive ﬂow cytometry data (3) and the previously re-
ported time course of leukocyte inﬁltration into the
infarct (7) suggest that leukocytes may indeed be
the primary cardiac PET signal source.
The puzzling observation of heterogeneity, i.e.,
68Ga-pentixafor enrichment in 3 of 7 patients or
55 of 204 ischemic myocardial segments, provides
food for thought and is potentially exciting because
the method clearly distinguishes patient subgroups
in a seemingly homogeneous cohort. It is now of
paramount importance to identify whether the
cardiac 68Ga-pentixafor PET signal predicts post-MI
recovery. One hypothetical scenario posits that
only patients with a high number of recruited in-
ﬂammatory neutrophils and monocytes showed
68Ga-pentixafor uptake, whereas myocardial seg-
ments that are undergoing resolution of inﬂamma-
tion, with declining neutrophil numbers, did not. The
observation that the PET signal was higher at earlier
times and in severely injured segments, and lowered
by angiotensin-converting enzymeinhibitor therapy
which decreases myocardial leukocyte levels (13),
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1429supports this line of thought. If this hy-
pothetical scenario is true, 68Ga-pentixafor PET
imaging may identify patients at risk for post-MI
heart failure, and the method could be used to
study the cardiac effects of anti-inﬂammatory in-
terventions aiming at the prevention of post-MI
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